Xiamen Innovax Biotech's Commitment to HPV Prevention at IPVS 2026

Xiamen Innovax Biotech's Involvement at IPVS 2026

Xiamen Innovax Biotech Co., Ltd. (IX) made a significant appearance at the 38th Annual Conference of the International Papillomavirus Society (IPVS 2026), which took place from October 22 to 25, 2026, in Athens, Greece. This landmark event gathered international experts to discuss essential advancements in HPV (human papillomavirus) research, prevention strategies, and shared goals in combating cervical cancer.

Collaborative Discussions on HPV Prevention

Under the theme “Together Against HPV,” Innovax welcomed attendees at their booth, facilitating discussions pertaining to vaccine innovations, recent scientific findings, accessibility issues, and the critical nature of international collaboration in the fight against HPV. The booth featured an interactive message wall where participants could express their views and commitment to HPV prevention, fostering a sense of community and shared responsibility.

Dr. Nana A. Ansah, from the Navrongo Health Research Centre in Ghana, presented interim results from the PATH study titled “Single-dose HPV Immunobridging Study with New Vaccines” (SHINE I; CVIA 104), a crucial multinational Phase II-III trial comparing the immunogenicity and safety of a single dose of the Cecolin 9 vaccine against Gardasil 9. Conducted in Ghana and the Philippines, this study highlights the innovative strides IX is making within global public health. Final data from this significant trial is anticipated in 2028, representing a crucial step forward in cervical cancer prevention.

Advancements and Innovations in HPV Vaccines

Innovax's portfolio includes the WHO-prequalified bivalent HPV vaccine, Cecolin, and the next-generation 9-valent HPV vaccine, Cecolin 9, which was launched in China in 2025. By leveraging its proprietary E. coli-derived technology platform for virus-like particles (VLP), IX is pushing boundaries in vaccine innovation, scalable manufacturing, and fostering international partnerships. This approach aims not only at innovation in vaccine technology but also at making these vaccines accessible to populations in need.

Commitment to local needs and challenges in public health is essential, as emphasized by IX during the conference. They focused on capturing diverse global voices and viewpoints, which are vital in crafting solutions that effectively address regional healthcare challenges. Innovax is dedicated to technology transfer and building local capacities to strengthen the sustainable supply of vaccines, thus directly targeting local public health needs.

A Commitment to Global Health Initiatives

The conference reinforced IX's dedication to listening to the global HPV community and learning from these interactions to better collaborate and address the challenges posed by cervical cancer globally. With a mission centered around providing high-quality and affordable vaccines, IX continues to build partnerships across the world to drive HPV prevention strategies forward and work towards the collective goal of eliminating cervical cancer.

Overall, IX's presentation and participation at IPVS 2026 not only highlight their advancements in HPV vaccine development but also their commitment to global health initiatives aimed at reducing the incidence of cervical cancer worldwide. Through collaboration and innovation, Xiamen Innovax Biotech is indeed carving a path towards a healthier, HPV-free future.